Arnuity Ellipta costs around $198 to $281 at retail for a 30-day supply, depending on the dose, because it’s a brand-name inhaler with no approved generic alternative. That single factor drives most of the cost. Without generic competition to push prices down, GSK (the manufacturer) sets the price, and pharmacies, insurers, and patients have limited leverage.
No Generic Competition Exists
The active ingredient in Arnuity Ellipta is fluticasone furoate, a newer form of a well-known steroid used to control asthma. While the FDA has approved a generic version of the older Flovent HFA inhaler (which uses a different form called fluticasone propionate), no generic version of Arnuity Ellipta has been approved. That distinction matters because the two forms of fluticasone are not interchangeable. They’re different molecules with different formulations, delivered through different inhaler devices.
The Ellipta inhaler itself adds another layer of protection. Generic drugmakers don’t just need to replicate the medication. They also need to demonstrate that their device delivers the drug in the same way. Dry powder inhalers like the Ellipta are harder to copy than standard metered-dose inhalers, and the device design may be covered by its own patents. Until a generic manufacturer clears both the drug and device hurdles at the FDA, Arnuity Ellipta remains the only option for patients prescribed fluticasone furoate in this format.
A Slightly Different Drug at a Higher Price
Fluticasone furoate (the ingredient in Arnuity) and fluticasone propionate (the ingredient in older, now-generic inhalers) sound nearly identical, but they behave differently in the body. Fluticasone furoate binds more strongly to steroid receptors in lung tissue, which allows it to work effectively with once-daily dosing instead of twice daily. For many patients, that’s a meaningful convenience advantage and can improve adherence.
Clinical comparisons between the two show similar overall effectiveness at reducing symptoms. In studies comparing the nasal spray versions of both drugs, fluticasone furoate began reducing symptoms on the first day of treatment, while fluticasone propionate took until the second day. Patients also tended to prefer the furoate formulation’s sensory characteristics. These are real but incremental benefits, and they give the manufacturer a basis for positioning Arnuity as a premium product rather than a direct substitute for cheaper alternatives.
A generic fluticasone propionate inhaler costs roughly $171 for a 30-day supply without insurance. Arnuity Ellipta runs about $212 for the same period at the 100 mcg strength. The gap isn’t enormous in dollar terms, but it adds up over months and years of daily use, and the generic price will likely continue to drop as more competitors enter the market.
What You’ll Actually Pay
Your out-of-pocket cost depends heavily on your insurance situation. With a GoodRx coupon, the lowest available price for the 50 mcg or 100 mcg strength is around $137 at pharmacies like CVS and Target. Walmart and Walgreens tend to run higher, closer to $200 to $212. The 200 mcg strength costs more, with a retail price near $281 and coupon prices around $168.
If you have Medicare Part D, your costs have shifted in recent years. Most asthma and COPD inhalers, including Arnuity Ellipta, are typically placed on a preferred brand tier. But Medicare plans have been rapidly replacing flat copays with coinsurance, where you pay a percentage of the drug’s cost rather than a fixed dollar amount. According to the American Lung Association, 97% of standalone Part D plans used coinsurance for asthma and COPD drugs in 2026, up from about 39% in 2024. That means your share of the cost now tracks directly with the drug’s price, making expensive inhalers hit your wallet harder.
Ways to Lower the Cost
GSK has capped out-of-pocket costs at $35 per month for eligible patients across its entire portfolio of asthma and COPD inhalers, including Arnuity Ellipta. This applies to commercially insured patients. If you’re uninsured or underinsured, GSK also runs a patient assistance program through GSKforYou that provides medications at no cost to people who meet income requirements.
The major catch: if you’re enrolled in a federal government insurance program like Medicare, Medicaid, or TRICARE, you’re not eligible for the copay cap or most manufacturer coupon programs. That’s a federal restriction, not a GSK policy, and it leaves Medicare patients particularly exposed to rising coinsurance percentages.
If cost is a primary concern and your doctor agrees, switching to a generic fluticasone propionate inhaler is the most straightforward way to save. You’ll need to use it twice a day instead of once, but the medication class and overall effectiveness are comparable. That conversation is worth having, especially if the once-daily convenience of Arnuity isn’t making a noticeable difference in how consistently you use your inhaler.